

KFIN/CERT13(3)/MAR/2023 April 7, 2023

Mr. Ajay Nadkarni M/s. GlaxoSmithKline Pharmaceuticals Limited Dr. Annie Besant Road Worli Mumbai-400025.

Sub : Investor Grievance Certificate for the quarter ended March 31, 2023.

Dear Sir,

With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended March 31, 2023.

Description of	Opening	Received during	Attended/Resolved	Pending as on
Complaint	Balance as on	the Period	during the Period	31.03.2023
	01.01.2023	01.01.2023 to	01.01.2023 to	
		31.03.2023	31.03.2023	
Non-receipt of	NIL	09	09	NIL
Dividend				
Non-receipt of	NIL	NIL	NIL	NIL
Annual reports				
Non receipt of	NIL	07	07	NIL
shares				
SEBI	NIL	07	07	NIL
Stock Exchange	NIL	NIL	NIL	NIL
Total	NIL	23	23	NIL

This is for your information and record.

Thanking you,

Yours faithfully For KFin Technologies Limited

Rajitha Cholleti Dy. Vice President

KFin Technologies Limited 🔘

(Formerly known as KFin Technologies Private Limited)

Registered & Corporate Office: Selenium Building, Tower-B, Plot No- 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddi, Telangana, India, 500032.

CIN: L72400TG2017PLC117649